Patent Term Extension Application for RHAPSIDO (remibrutinib), Patent No. 9,512,084 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2025-E-6201

Patent Term Extension Application for RHAPSIDO (remibrutinib), Patent No. 9,512,084

Documents

Comments

Description

OPEN

Comment Period OpensNov 17, 2025

Type	Title	Posted	Comments	Status
Other	Letter from U.S Patent and Trademark Office to FDA CDER	Mar 25, 2026	--

CDER

Patent Term Extension Application

Novartis Biomedical Research

Novartis AG

RHAPSIDO (remibrutinib)

Patent No. 9,512,084

OPEN